CoChat

Inhaled pirfenidone solution (AP01) for IPF: a randomised, open-label, dose–response trial

Open access

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

Introduction: Oral pirfenidone reduces lung function decline and mortality in patients with idiopathic pulmonary fibrosis (IPF). Systemic exposure can have significant side effects, including nausea, rash, photosensitivity, weight loss and fatigue. Reduced doses may be suboptimal in slowing disease progression. Methods: This phase 1b, randomised, open-label, dose–response trial at 25 sites in six countries (Australian New Zealand Clinical Trials Registry (ANZCTR) registration number ACTRN12618001838202) assessed safety, tolerability and efficacy of inhaled pirfenidone (AP01) in IPF. Patients diagnosed within 5 years, with forced vital capacity (FVC) 40%–90% predicted, and intolerant, unwilling or ineligible for oral pirfenidone or nintedanib were randomly assigned 1:1 to nebulised AP01 50 mg once per day or 100 mg two times per day for up to 72 weeks. Results: We present results for week 24, the primary endpoint and week 48 for comparability with published trials of antifibrotics. Week 72 data will be reported as a separate analysis pooled with the ongoing open-label extension study. Ninety-one patients (50 mg once per day: n=46, 100 mg two times per day: n=45) were enrolled from May 2019 to April 2020. The most common treatment-related adverse events (frequency, % of patients) were all mild or moderate and included cough (14, 15.4%), rash (11, 12.1%), nausea (8, 8.8%), throat irritation (5, 5.5%), fatigue (4, 4.4%) and taste disorder, dizziness and dyspnoea (three each, 3.3%). Changes in FVC % predicted over 24 and 48 weeks, respectively, were −2.5 (95% CI −5.3 to 0.4, −88 mL) and −4.9 (−7.5 to −2.3,–188 mL) in the 50 mg once per day and 0.6 (−2.2 to 3.4, 10 mL) and −0.4 (−3.2 to 2.3, −34 mL) in the 100 mg two times per day group. Discussion: Side effects commonly associated with oral pirfenidone in other clinical trials were less frequent with AP01. Mean FVC % predicted remained stable in the 100 mg two times per day group. Further study of AP01 is warranted. Trial registration number: ACTRN12618001838202 Australian New Zealand Clinical Trials Registry.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/thorax-2022-219391

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Research works printed but not linked: 3

  1. 1. West A, et al. Thorax 2023;78:882-889. doi:10.1136/thorax-2022-219391 Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. . by guest on December 20, 2025 http://thorax.bmj.com/ Downloaded from 22 March 2023. 10.1136/thorax-2022-219391 on Thorax: first published as Interstitial lung disease Bellerophon Therapeutics, Biogen, Bristol Myers Squibb, Fibrogen, Nitto, Promedior, Respivant and Veracyte.
  2. 10. Lalla D, Bengston L, Raimundo K, et al. Pirfenidone and nintedanib compliance and persistence in A real world setting. Am J Respir Crit Care Med 2017;195:A5351.
  3. 28. West A, et al. Thorax 2023;78:882-889. doi:10.1136/thorax-2022-219391 Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. . by guest on December 20, 2025 http://thorax.bmj.com/ Downloaded from 22 March 2023. 10.1136/thorax-2022-219391 on Thorax: first published as

Cited by

See all 77

Metadata

Authors
West, A., Chaudhuri, N., Barczyk, A., Wilsher, M. L., Hopkins, P., Glaspole, I., Corte, T. J., Šterclová, M., Veale, A., Jassem, E., Wijsenbeek, M. S., Grainge, C., Piotrowski, W., Raghu, G., Shaffer, M. L., Nair, D., Freeman, L., Otto, K., & Montgomery, A. B.
Affiliations
  • Guy's Hospital (GB)
  • University of Ulster (GB)
  • Medical University of Silesia (PL)
  • Auckland District Health Board (NZ)
  • Prince Charles Hospital (AU)
  • The Alfred Hospital (AU)
  • Royal Prince Alfred Hospital (AU)
  • Thomayer University Hospital (CZ)
  • Gdańsk Medical University (PL)
  • Erasmus MC (NL)
  • Hunter Medical Research Institute (AU)
  • Medical University of Lodz (PL)
  • University of Washington (US)
Corresponding author
Montgomery, A Bruce
Venue
Thorax
Publisher
BMJ
Published
2023-03-22
Volume
78
Issue
9
Pages
882-889
ISSN
  • 0040-6376 (ISSN-L)
  • 1468-3296
OpenAlex
W4353042437
Cited by
67
References
23
Citations by year
2026: 13 · 2025: 29 · 2024: 19 · 2023: 6
FWCI
12.29
Type
journal article
Language
en
Open access
Locations
  • Thorax (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
  • Ulster University Research Portal (Ulster University) (acceptedVersion, cc-by)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
  • HighWire Press Open Archive (submittedVersion)
  • NOVA (University of Newcastle Australia) (submittedVersion)
Funders
Avalyn Pharma (Not applicable)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
Keywords
pirfenidone, idiopathic pulmonary fibrosis, pulmonary drug delivery, antifibrotic therapy, forced vital capacity decline, lung function, dose-response relationship, safety and tolerability, nintedanib
MeSH terms
Aged, Aged, 80 and over, Anti-Inflammatory Agents, Non-Steroidal, Australia, Female, Humans, Male, Middle Aged, Pyridones, Vital Capacity, Treatment Outcome, Idiopathic Pulmonary Fibrosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inhaled pirfenidone solution (AP01) for IPF: a randomised, open-label, dose–response trial. https://app.cochat.ai/papers/10.1136/thorax-2022-219391
The paper
West, A., Chaudhuri, N., Barczyk, A., Wilsher, M. L., Hopkins, P., Glaspole, I., Corte, T. J., Šterclová, M., Veale, A., Jassem, E., Wijsenbeek, M. S., Grainge, C., Piotrowski, W., Raghu, G., Shaffer, M. L., Nair, D., Freeman, L., Otto, K., & Montgomery, A. B. (2023). Inhaled pirfenidone solution (AP01) for IPF: a randomised, open-label, dose–response trial. Thorax. https://doi.org/10.1136/thorax-2022-219391

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.